Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
04/06/2026 07:46
BRIEF-Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study June 4 (Reuters) - Suven Life Sciences Ltd SUVP.NS:
REPORTS POSITIVE DSMB SAFETY REVIEW FOR PHASE 3 MASUPIRDINE STUDY
Source text: ID:nBSE5mdpl6
Further company coverage: SUVP.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees